MARINER Trial: Multiparametric Cardiac PET for CAV Surveillance After Heart Transplantation
Multiparametric Cardiac Positron Emission Tomography for Cardiac Allograft Vasculopathy Surveillance After Heart Transplantation
Ottawa Heart Institute Research Corporation
576 participants
Jan 8, 2024
INTERVENTIONAL
Conditions
Summary
Cardiac allograft vasculopathy (CAV) is a common complication affecting heart transplant patients. This condition causes narrowing of the heart arteries leading to graft dysfunction. Surveillance for CAV is vital; however an ideal approach has not been established. The goal of this study is to assess whether noninvasive positron emission tomography (PET) based surveillance is non-inferior to invasive coronary angiography (ICA) surveillance.
Eligibility
Inclusion Criteria3
- Post heart transplant 2-10 years.
- Age ≥18 years.
- Able to provide informed consent.
Exclusion Criteria8
- Contraindication to dipyridamole due to severe aortic stenosis.
- Contraindication to dipyridamole due to 2:1 or greater AV block without pacemaker.
- Contraindication to dipyridamole due to severe bronchospasm.
- Unable to undergo coronary angiography due to allergy to iodinated contrast.
- Unable to undergo coronary angiography due to glomerular filtration rate ≤30 mL/min/1.73 m2. for non-dialysis patients as determined by local laboratory analysis.
- Unable to undergo coronary angiography due to unsuitable vascular access.
- Treated rejection ≤1-month.
- Unstable angina or MI ≤7 days.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Patients will undergo annual CAV surveillance with ICA
Patients will undergo annual CAV surveillance with PET
Locations(5)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06089486